Table 3.
Univariate analyses of various clinicopathological parameters in relation to progression‐free survival of patients with bladder cancer
| Patients | Progression‐free survival | ||
|---|---|---|---|
| Parameters | No. cases (%) | No. events | P‐valuea |
| Age (years) | |||
| <65 | 46 (44) | 2 | 0.2971 |
| ≥65 | 59 (56) | 6 | |
| Gender | |||
| Male | 84 (80) | 6 | 0.6708 |
| Female | 21 (20) | 2 | |
| Stage | |||
| pTa | 78 (74) | 8 | 0.1050 |
| pT1 | 27 (26) | 0 | |
| Grade | |||
| G1 + G2 | 90 (86) | 6 | 0.3695 |
| G3 | 15 (14) | 2 | |
| Concominant CIS | |||
| No | 98 (93) | 7 | 0.4638 |
| Yes | 7 (7) | 1 | |
| No. tumors | |||
| Single | 76 (72) | 4 | 0.1624 |
| Multiple (2–7) | 29 (28) | 4 | |
| Tumor size | |||
| <3 cm | 101 (96) | 8 | 0.6123 |
| ≥3 cm | 4 (4) | 0 | |
| Tumor status | |||
| Primary | 76 (72) | 4 | 0.1830 |
| Recurrent | 29 (28) | 4 | |
| DDX39 expression | |||
| Low (positive cells <50%) | 39 (37) | 6 | 0.0083 |
| High (positive cells ≥50%) | 66 (63) | 2 | |
a
Log–rank test. CIS, carcinoma in situ.